TABLE 1.
Assessment of protection against ciliostasis associated with BeauR-M41(S1) and BeauR-QX(S1) vaccination following challenge with M41-CK or QX
| Vaccination/challenge | % ciliary activity (mean ± SD)a |
No. of birds with 90% ciliary activity/total birds examinedb |
% of group protectedc |
|---|---|---|---|
| Mock/Mock | 92 ± 8.2 | 5/5 | NA |
| Mock/M41 | 2 ± 1.4 | 0/5 | 0 |
| BeauR-M41(S1)/M41 | 9 ± 16.3 | 0/5 | 0 |
| Mock/QX | 1 ± 0 | 0/5 | 0 |
| BeauR-QX(S1)/QX | 1 ± 1.4 | 0/5 | 0 |
That is, the mean ciliary activity per group calculated from ciliostasis scores for 10 tracheal rings per individual bird using the following formula: [(total ciliostasis score of tracheal rings)/40] × 100.
Ciliary activity was assessed according to European Pharmacopeia standards (27), wherein a bird is deemed protected against ciliostasis if no fewer than 9 of 10 tracheal rings per bird show normal ciliary activity (>50% ciliary activity retained).
A vaccine is considered efficacious at conferring protection against ciliostasis when 80% or more of the birds in a group were protected. NA, not applicable.